Management Team

Scientific Advisory Team

Our scientific advisers have over 125 years of cumulative expertise, experience, and knowledge on all aspects of drug development. By collaborating and taking the clients’ needs into consideration, they create the best strategy to accelerate molecules to medicines and make their companies’ resources available for the project.

Dr. Chris Senanayake

CEO at TCG GreenChem, Inc.

CSO at TCG Lifesciences Private Limited

Inspirational leader with 30 years experience in the pharmaceutical industry with extensive knowledge and experience in all drug development processes, company governance committees and commercialization
Instrumental in delivering several multi billion-dollar in an accelerated manner to the market. Crixivan™, Lunesta™, Formotorol and Pristiq™ (Desvenlafaxine) and Jardiance™
Received the prestigious Swiss Siegfried Gold Medal Award for development of practical processes for APIs and Process Chemistry via the use of sustainable and green manufacturing processes, 2010
500 Publications in nationally known scientific journals, >150 patents for chemical processes, discovery, and drug development, etc., >150 invited lectures
Serves as the Board of Editors of Organic Synthesis, Advance Synthesis of Catalysis, Organic Process Research and Development, Asian Journal of Organic Chemistry and Beilstein Journal of Organic Chemistry

Dr. Joseph D. Armstrong, III

Chief Operating Officer and Global Head of Business at TCG GreenChem, Inc.

High energy scientific and executive leader with 28 years experience at Merck & Co., Inc. in Process Research, Formulation Development, and Project Management with deep knowledge and experience of all drug discovery and development processes to support IND to NDA filings.
As the Merck Preclinical Integration Lead (Process R&D, Formulation R&D, DMPK, Safety Assessment, and Clinical Supplies) for the merger with Schering Plough, created a multidisciplinary organization that leveraged development knowledge to accelerate identification of Preclinical Candidates and their rapid entry into the clinic and beyond.
Led the cross-functional team that filed the drug Januvia™ for the treatment of type II diabetes in < 4 years by executing new green and sustainable technologies and strategies.
Led the Process R&D Team that discovered the novel asymmetric hydrogenation process for the preparation of Sitagliptin, the active ingredient in Januvia™. This team received the Thomas Edison award, the EU IChemE Aztra-Zeneca Award for Green Chemistry and Engineering and the US Presidential Green Chemistry Challenge Award.

Dr. Robert Wenslow

US & EU at Crystal Pharmatech

21 years Pharmaceutical solid-state Chemistry
14 years at Merck (Januvia, Proscar)
Form selection, formulation development, crystallization of over 500 compounds
Driving in-silico drug development
Expert witness
Expertise in solid-state NMR, maintaining direct responsibilities of solid-state NMR facility at Merck
Established first analytical research group in Ireland for Merck
Ph.D. in Chemistry from Pennsylvania State University
Invited lecturer at over 10 conferences
Published more than 25 peer reviewed journal articles
Co-author on over 10 patents

Dr. Yonqgiang Li

Founder and CEO of Candoo Pharmatech

Member of AAPS, ACS, and RAPS Societies
Served as a Physical Analysis Expert Council Member and Chair of the Organic Impurities Expert Panel at the U.S. Pharmacopeia for 10 years
Served as Interim Head at Aveo Oncology
Vice-President and Head of CMC Regulatory Affairs at Vertex Pharmaceuticals from 2008 to 2011. He worked on key projects such as Incivek for Hepatitis and Ivacaftor for cystic fibrosis during his tenure.
Chair of the AAPS Regulatory Science section in 2009
Senior Director of Regulatory (CMC) at Cubist Pharmaceuticals from 2005-2008
Director-II of World Wide Regulatory Affairs (CMC) at Wyeth Pharmaceuticals from 2004-2005, working on Atiinfectives (Zosyn and Tygacil) and Cardiovascular and Gastrointestinal (Protonix) products
Senior Director of Technical Regulatory Affairs at Sepracor for 6 years, managing development and post-approval activities for all company projects including Xoponex (R-albuterol), Lunesta (S-zopiclone), and Brovana (R, R-Formoterol)
Research Investigator and Manager-WWRA-CMC at Bristol-Myers Squibb for 7 years
Provided RA-CMC leadership for more than 12 NDAs, numerous sNDAs, and around 50 INDs
Expert in the science and risk-based regulatory approaches to develop innovative CMC strategies aimed at expediting development, registration, and life-cycle management

T. Shantha Raju

Biologics Consultant

Former VP and Head of Protein Sciences

CHO Plus, Inc.

Research and development expert with more than 25 years of experience in biotherapeutics, including mAbs, proteins, vaccines, gene therapy, cell therapy, etc.
Key player in the successful development of Herceptin, Avastin, Xolair, Raptiva, Remicade, Stelara, Simponi, Darzalex, Infinzi, etc. at Genentech, Janssen, and Medimmune.
Over 40 research papers, review articles, and book chapters published
Member of editorial boards of several leading journals
His book entitled “Co- and Post-Translational Modifications of Therapeutic Antibodies and Proteins” was recently published by Wiley